Morse BL, Alberts JJ, Posada MM, et al
NO FILLERS OR BINDERS Allergens None
After 6 months of therapy, those taking GLP1 drugs showed: Elevated risk of androgenic alopecia Elevated risk of nonscarring hair loss No significant change in telogen effluvium risk No significant change in alopecia areata risk At the 12-month mark, the pattern had shifted slightly: Continued higher risk for androgenic alopecia Continued higher risk for nonscarring hair loss A newly increased risk of telogen effluvium Still no change in risk of alopecia areata The apparent absence of a link between GLP1 medications and alopecia areata is especially notable, as isolated case reports have previously suggested an association
This timeframe may depend on how well you respond to the medication, if you experience side effects, or if you may need to consider another medication
Individual results depend on several factors, including the baseline melanin index, lifestyle factors (such as sun exposure), and consistency of treatment
In type 2 diabetes, preprandial administration of native GLP-1 reduces plasma glucose and improves glucose tolerance [15]
